Basal-like breast cancers (BLBCs) are aggressive tumors with high relapse rates and poor survival. We recently reported that >70% of primary BLBCs express the oncogenic transcription/translation factor Y-box binding protein-1 (YB-1) and silencing it with small interfering RNAs (siRNAs) attenuates the growth of BLBC cell lines. To understand the basis of these earlier findings, we profiled YB-1:DNA complexes by chromatin immunoprecipitation (ChIP)-on-chip. Several tumor growth-promoting genes such as MET, CD44, CD49f, WNT and NOTCH family members were identified. In addition, YB-1 and MET are coordinately expressed in BLBC cell lines, as well as in normal human mammary progenitor cells. MET was confirmed to be a YB-1 target through traditional ChIP and gel-shift assays. More specifically, YB-1 binds to À1018 bp on the MET promoter. Silencing YB-1 with siRNA decreased MET promoter activity, transcripts, as well as protein levels and signaling. Conversely, expressing wild-type YB-1 or a constitutively active mutant YB-1 (D102) increased MET expression. Finally, silencing YB-1 or MET attenuated anchorageindependent growth of BLBC cell lines. Together, these findings implicate MET as a target of YB-1 that work in concert to promote BLBC growth.
Introduction
Basal-like breast cancers (BLBCs) remain as one of the greatest challenges given that the probability of survival beyond 2 years is only 30% (Sorlie et al., 2001) . Because BLBCs do not express estrogen receptors, progesterone receptors or HER-2, they are unresponsive to antiestrogens (Dunn and Ford, 2007) or Herceptin that target these gene products (Colozza et al., 2007) . Therefore, much effort is now focused on identifying new molecular targets in BLBCs. One target of current interest is the transcription/translation factor Y-box binding protein-1 (YB-1) because of its documented high expression in approximately 70% of BLBCs (Stratford et al., 2007) and its association with poor survival (Habibi et al., 2008) . YB-1 is consistently associated with high rates of relapse in virtually all breast cancer subtypes including BLBC (Habibi et al., 2008) . Complimenting the strength of YB-1 as a biomarker of aggressive cancer, we reported that inhibiting it with small interfering RNAs (siRNAs) attenuates the growth of BLBC cell lines (Lee et al., 2008) . YB-1 is known to stimulate cell growth by binding to inverse CAAT boxes of many genes, thereby inducing their expression. Examples include EGFR (epidermal growth factor receptor), HER-2 and TOPOII (topoisomerase 2) (Okamoto et al., 2000; Wu et al., 2006) . It has been suggested that such YB-1-mediated activation of EGFR transcription also promotes the growth of BLBCs (Wu et al., 2006) . The induction of EGFR expression is dependent on phosphorylation of YB-1 at S102 (Wu et al., 2006; Stratford et al., 2007) , which is achieved by serine/threonine kinases Akt (Sutherland et al., 2005) or RSK (Stratford et al., 2008) leading to nuclear translocation. Importantly, nuclear YB-1 has been reported in many instances to be a universal biomarker for drug resistance, thus understanding how it regulates gene expression is essential (Kuwano et al., 2004) . Given this, it is of particular interest to understand the specific target genes responsible for the growth dysregulation of YB-1 overexpressing BLBC cells.
Another gene associated with poor outcomes and a greater risk of metastasis in BLBCs is MET (Welm et al., 2005) . The MET gene encodes a cell surface tyrosine kinase receptor for hepatoctye growth factor (HGF, also known as scatter factor). HGF is a pleiotropic cytokine with pro-migratory, anti-apoptotic and mitogenic activities (Trusolino and Comoglio, 2002; Birchmeier et al., 2003; Leo et al., 2007) . Once activated, MET can promote cancer cells to proliferate and migrate and it has thus become another potential therapeutic target (Yoshida et al., 2004) .
To understand how YB-1 regulates the growth of BLBC at the transcriptional level, we performed genome-wide chromatin immunoprecipitation (ChIP)-on-chip (COC) analyses using promoter arrays. These revealed a subset of YB-1 target genes associated with the basal-like signature including MET and other genes expressed by normal progenitor and malignant mammary cells such as CD44, CD49f and several members of the NOTCH and WNT families. Further studies were then undertaken to investigate how YB-1 regulates MET expression.
Results

COC suggests YB-1 regulates MET
COC was undertaken to systematically identify a full list of potential targets of YB-1 in SUM149 BLBC cells. The results revealed that YB-1 potentially interacts with >6000 candidate promoters. A high proportion of these encode enzymes, kinases, transporters and known or potential growth factor receptors ( Figure 1a ) (for a complete list, see Supplementary Table 1) . Notable among the latter was MET (Table 1) . CD44 (OrianRousseau et al., 2002) and CD49f (Trusolino et al., 2001) were also found to be potential YB-1 target genes and notably both are reported earlier to bind to and enhance MET activation (Boccaccio and Comoglio, 2006) . Several members of the NOTCH and WNT pathways were also identified (Table 1) . Their potential functional relationships to one another, in terms of signal transduction activation, are illustrated using Ingenuity Pathway Analysis software (Figure 1b) . We highlight that two major signaling nodes are created using this approach; one that involves the MET/CD44/ CD49f signaling complex and the other that includes WNT/NOTCH interactions. Although it is beyond the scope of this work to validate all of the YB-1 target genes associated with these signaling networks, this preliminary analysis does suggest that there are common features of YB-1 responsive genes that could have an important bearing on cell growth control.
P-YB-1
(S102) and MET are coordinately expressed in BLBC cell lines To investigate if there is a relationship between levels of MET and YB-1 protein, a panel of breast cancer cell lines was screened. Levels of total YB-1 protein were consistent across all cell lines, but P-YB-1 (S102) levels were higher in the BLBC cells. Strikingly, MET was expressed exclusively in the BLBC cell lines. Like many transcription factors, YB-1's access to the genome is governed by phosphorylation (Sutherland et al., 2005) . Here we show that P-YB-1 (S102) was intensely expressed in the nucleus of SUM149 and MDA-MB-231 cells. MET was also expressed at considerable levels in both SUM149 and MDA-MB-231 based on immunofluorescence (Figure 2b ). This was further confirmed by immunoblotting (data not shown).
Total YB-1 and MET are coexpressed in normal human mammary progenitor cells We asked whether YB-1 transcripts are present in populations of the most primitive normal human mammary progenitors that can be reproducibly isolated at high purities (30-50% ); that is, bipotential progenitors that produce mixed colonies containing both mature luminal and myoepithelial cell progeny. Suspension cultures containing bipotent progenitors were isolated from freshly thawed aliquots of reduction mammoplasty cells taken from three different individuals. The mRNA from these samples was amplified for YB-1 and MET by quantitative reverse transcriptase-PCR. In addition, we evaluated the expression of YB-1 and MET in mammoplasty cells that were isolated and subsequently cultured for 3 days in media that specifically enriches for progenitors, where the proportion of progenitors increased from B5% in the freshly thawed isolates to 30-50% in the selective media. YB-1 and MET mRNA were expressed in the bipotential progenitor populations regardless of the culturing method (Figure 2c ). However, the levels of YB-1 transcripts in these cells were up to 2000 times lower than in the cancer cell lines and the levels of MET mRNA were as much as 300 times lower (data not shown). Nevertheless, there was a strong correlation (r 2 ¼ 0.8785) between the levels of YB-1 and MET mRNA in the normal progenitor-enriched samples ( Figure 2d ). This indicates for the first time that YB-1 and MET transcripts are both detectable in a very primitive normal mammary subpopulation albeit at very low levels compared with cancer cell lines.
Verification that YB-1 binds to the promoter of MET To obtain more direct evidence that YB-1 binds to the MET promoter in BLBC cells, traditional ChIP experiments were carried out on extracts of three BLBC (SUM149, MDA-MB-213 and MDA-MB-468) cell lines, as well as, from a primary tumor that developed from SUM149 cells injected into a NOD/SCID mouse. PCR amplifications were performed using three primer sets designed to flank potential YB-1 binding sites on the MET promoter referred to as MET 1, MET 2 and MET 3 (Figure 3a , top). YB-1:MET promoter binding was validated using MET 1 primers and this was evident in each of the BLBC cell lines and the xenograft cells (Figure 3a , bottom, left). Yet the putative YB-1-responsive elements that would have been amplified by the MET 2 and MET 3 primers were not authentic binding sites based on lack of amplification ( Figure 3a , bottom, right). Using this strategy, we localized YB-1 binding sites to the MET 1 region that contains six potential binding sites. To determine which of the potential YB-1 binding sites was most important, five oligonucleotides (oligo 2 contained two YB-1-responsive elements in close proximity to one another) were designed to the putative binding sites in the MET 1 region and electrophoretic mobility shift assay (EMSA) was then performed (data not shown). The results of these assays revealed that oligo 1 (À1151 to À1180) and 4 (À1006 to À1035) elicited the strongest shifts in the presence of a nuclear extract from SUM149 cells (Figure 3b ). This was confirmed with MDA-MB-231 nuclear extracts (data not shown). Both oligos showed a strong supershift with the addition of the YB-1 antibody but not a cyclic AMP response-element binding (CREB) protein antibody, indicating the specificity of the YB-1 binding. Furthering this observation, mutation of the YB-1-responsive element in oligo 4 resulted in loss of binding, whereas this was not the case with oligo 1 (Figure 3c ). Therefore, it can be concluded that a bona fide YB-1-responsive element on the MET promoter resides À1018 bp upstream of the translational start site while YB-1 binding to the oligo 1 region must be indirect.
To investigate this apparent association further, the introduction of either Flag:YB-1 or constitutively active Flag:YB-1(D102) increased MET protein levels in SUM149 and HCC1937 cells compared with the empty vector, yet the inactive A102 mutant did not (Figure 4a ). The introduction of siRNA designed to silence YB-1 reduced MET protein and mRNA expression by 40-60% in SUM149 and MDA-MB-231 cells Figure 1 Categorization of YB-1 COC data into functional groups and schematic presentation of the possible interactions among the select genes that are linked to primitive cells and tumor initiation. (a) Genes were grouped into 15 functional categories. The largest known group was represented by genes that encode enzymes using Ingenuity Pathway Analyses. Enumeration of the genes in each category is found in the list. (b) From the B6000 potential YB-1 targets identified by COC, a group of genes involved in self-renewal and tumor initiation were identified. The way in which the protein products of these genes interact with one another and thereby influence cell signaling is depicted. From this analysis, it is clear that there are several members of two common signaling nodes that are potentially regulated by YB-1. These nodes involve MET/CD44/CD49f and the WNT/NOTCH networks. Solid arrows indicate direct interactions, whereas broken arrows represent indirect relationships. COC, ChIP-on-chip. . Thus, inhibiting a major signal transduction pathway known to activate YB-1 also perturbs MET protein expression . These data provide evidence that YB-1 phosphorylation is important for its control of MET expression.
YB-1 induces MET in BLBC
Silencing YB-1 or MET with siRNA inhibits HGFstimulated signaling and anchorage-independent growth Because HGF is the major stimulus for MET receptor, we expected that inhibiting YB-1 would interfere with this important signaling pathway. In support of this idea, silencing YB-1 for 96 h inhibited HGF-mediated signaling through MET given that Gab-1 phosphorylation was suppressed ( Figure 5a ). Silencing YB-1 with siYB-1 #3 remarkably suppressed the expression of the MET receptor and, therefore, HGF-induced signaling through Gab-1. We also silenced MET itself as a positive control to show that HGF must use this receptor to elicit signaling through Gab-1 (Figure 5a ). It is noted that, the partial suppression of MET with siYB-1 #2 was not enough to fully block HGF-induced signaling. This is likely because there was enough residual MET receptor present to transmit the signal. Taken together, these results indicate that the expression and activity of MET in BLBC cells is at least partly dependent on YB-1. To study the effect of YB-1 and MET knockdown on the proliferative activity of BLBC cell lines, the clonogenic ability of siRNA-treated SUM149 and MDA-MB-231 cells in soft agar assays was analysed in cultures enriched with HGF. Both cell lines showed greater sensitivity to the loss of YB-1 than MET interference, with up to a 90% reduction in colony-forming ability by siYB-1 #2 -treated SUM149 cells (Figure 5b ). However, a reduction of up to 57% in clonogenic ability of these cells was seen when MET was directly targeted. MDA-MB-231 cells were slightly less sensitive to either of these treatments (72% reduction with siYB-1 #2 and 34% with siMET, Figure 5c ). These data indicate that disruption of YB-1 leads to a remarkable suppression of anchorage-independent growth, some of which is attributable to loss of MET expression.
Our data collectively support the idea that MET is transcriptionally upregulated by YB-1 in BLBC. One could argue that high levels of MET may be due to gene amplification. To begin to address this, we performed comparative genomic hybridization on MDA-MB-231 and reported that amplifications were not found in the 7q31.1 where the MET gene resides (Shadeo and Lam, 2006) . Similarly, MET is not commonly amplified in primary BLBC based on the analysis of 10 tumors (Supplementary Figure 2) . These findings do not support the role of gene amplification causing the increased MET expression that is characteristic of these cells and reinforce the potential importance of other mechanisms such as YB-1-mediated upregulation.
Discussion
In this study, we present results of the first global COC analysis of genes potentially regulated by YB-1 in BLBC cells. This analysis revealed approximately 6000 candidate targets including many genes encoding growth factor receptors and their signaling intermediates. One of these was MET, which encodes the tyrosine kinase cell surface receptor for HGF and has been implicated earlier in primary human BLBCs (Charafe-Jauffret et al., 2006) . In addition, forced overexpression of MET together with Myc in murine mammary cells has been found to produce BLBC in mice (Welm et al., 2005) . While many aspects of MET activity have been well studied (Comoglio et al., 2008) , surprisingly little has been uncovered about its transcriptional regulation with the exception of evidence for a role of ETS (Gambarotta et al., 1996) , hypoxia inducible factor-1a (Pennacchietti et al., 2003) and b-catenin (Boon et al., 2002 ). In the studies described herein, using traditional MET expression was restricted to the BLBC cells lines, subtypes where P-YB-1 (S102) levels were also higher. (b) P-YB-1 (S102) was localized to the nucleus of the SUM149 and MDA-MB-231 cells. Levels of Met receptor protein were also visualized in the cell lines by immunofluorescence. 4,6-diamidino-2-phenylindole was used for nuclear staining. (c and d) YB-1 and MET receptor transcript levels in normal mammary progenitor cells were isolated from three different reduction mammoplasties. Cells were either isolated from freshly thawed tissues or from cells cultured in media that enriched for mammary progenitors. Samples were analysed by qRT-PCR assays for YB-1 and MET mRNA and normalized to endogenous TBP. YB-1 and MET mRNA tightly correlated across these samples (R 2 ¼ 0.8785). qRT-PCR, quantitative reverse transcriptase-PCR; TBP, TATA-box binding protein. Solid and open boxes refer to ATTG and CAAT binding regions, respectively. In addition, the location of confirmatory oligonucleotides used for subsequent gel-shift assays described below referred to as oligo 1 and 4 is also illustrated. Traditional ChIP analysis showed strong binding of YB-1 in the MET 1 region in both SUM149 and MDA-MB-468 extracts. In addition, ChIP from a SUM149 xenograft showed YB-1 binding in vivo at this site. Binding was not observed using primers to the MET2 or MET3 regions, for example in MDA-MB-468 cells. (b) EMSA analysis with MET oligos 1 and 4. The regions corresponding to these oligos were from À1151 to À1180 for oligo 1 and from À1006 to À1035 for oligo 4. In the absence of nuclear protein (lanes 1 and 6) no binding was observed. In contrast, the addition of nuclear extracts (lanes 2 and 7) resulted in binding, which could be competed with cold oligonucleotide (lanes 3 and 8) or by incubating the nuclear extracts with YB-1 antibody (lanes 4 and 9). Addition of YB-1 antibody causes a supershift (lanes 4 and 9), whereas addition of a CREB antibody did not (lanes 5 and 10) indicating site specificity. (c) Mutant oligonucleotides were next introduced to oligos 1 (from À1151 to À1180) and 4 (from À1006 to À1035) where the YB-1 binding site was changed to 5 0 -CCCC-3 0 . Loss of the putative YB-1 response element causes a reduction in YB-1 binding in oligo 4 (lane 7) but not oligo 1 (lane 3). CREB, cyclic AMP response-element binding-protein; YRE, YB-1-responsive elements, EMSA, electrophoretic mobility shift assay Figure 4 MET mRNA and protein levels and reporter activity can be modulated through YB-1. (a) SUM149 and HCC1937 cells were transiently transfected for 72 h with empty vector, Flag:YB-1(WT), Flag:YB-1(D102) or Flag:YB-1(A102). MET levels increased following the expression of Flag:YB-1(WT) and more so with Flag:YB-1(D102), whereas Flag:YB-1(A102) was unable to cause the same effect. (b) YB-1 knockdown with either siYB-1 #2 or siYB-1 #3 reduced MET protein expression in the SUM149 and MDA-MB-231 cell lines. Vinculin was used as a loading control. Similarly, shYB-1 expression lead to decreased MET receptor protein in SUM149 cells. (c) QRT-PCR revealed that transcript levels of MET were also reduced in YB-1 knockdown samples compared with cells treated with control siRNA for all cell lines. (d) SUM149 and MDA-MB-231 cells treated with siYB-1 #2 or siYB-1 #3 decreased MET reporter activity by 45 and 54%, respectively. Inhibition of YB-1 had no effect on the activity of empty vector, pGL2 basic, as expected. (e) In contrast, overexpression of wild-type YB-1 increased MET promoter activity which again was more so with Flag:YB-1(D102). Similar to transcription level, Flag:YB-1(A102) was unable to increase the promoter activity (f) OSU-03012 attenuated Akt activation resulting in reduced P-YB-1 S102 and eventually reduction of MET protein expression in SUM149 cells. Inhibition of PDK-1 signaling through OSU-03012 treatment also significantly inhibited MET mRNA levels based on qRT-PCR. SUM149 cells were treated with DMSO (black) or OSU-03012 (white) for 6 h. MET transcripts were significantly reduced by OSU-03012 compared with the DMSO-treated cells (Po0.05). qRT-PCR, quantitative reverse transcriptase-PCR; DMSO, dimethylsulfoxide. It should be noted that inhibiting YB-1 consistently had a greater effect on attenuating MET protein than it did on modulating MET mRNA levels. For example, when YB-1 expression was stably inhibited with short hairpin RNA, the levels of MET protein became virtually undetectable, yet MET mRNA was reduced by only B40-50%. This observation was confirmed using two different MET receptor antibodies. Consistent with these results, silencing YB-1 with a lentiviral short hairpin RNA vector yielded identical findings; the levels of MET protein were inhibited to a greater extent than could be explained by changes in mRNA. Although we show that the MET promoter is a direct target of YB-1, it may also influence its translation. Thus, additional regulatory avenues need to be explored to more fully understand the relationship between YB-1 and MET.
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As predicted by such a model, inhibiting YB-1 also markedly suppressed the growth of the BLBC cells under anchorage-independent conditions. Indeed, the inhibition obtained was even greater than that achieved by inhibiting MET alone, consistent with the COC findings indicating likely effects of YB-1 on other genes important to the growth of BLBC cells. These data suggest that targeting MET, as well as YB-1 could be useful therapeutic strategies for improving the treatment of BLBC in patients. In this regard, it is interesting to note that inhibitors of MET are already available and in clinical trials in other types of cancers (Comoglio et al., 2008) . Our group is actively developing inhibitors to YB-1.
Some of the other genes that YB-1 bound reportedly have stem/progenitor associations; for example, CD44, CD49f, c-KIT, BMI-1, and both NOTCH and WNT pathway elements (Stingl et al., 2006; Shipitsin et al., 2007; Mani et al., 2008; Raouf et al., 2008) . It is interesting to note that high expression of many of these genes has also been associated with human breast cancer cells that have an ability to initiate tumor formation in immunodeficient mice (Al-Hajj et al., 2003; Dontu et al., 2004; Farnie et al., 2007) . It might be speculated, therefore, that heightened expression of YB-1 is a key mechanism used by normal mammary stem cells to maintain their primitive status and one that is used and/ or highjacked by breast cancer stem cells. Further validation of the genes that YB-1 regulates in normal and malignant breast cells should therefore be of interest to understand why YB-1 expression correlates so strongly with breast cancer recurrence.
Materials and methods
Cell lines SUM149 cells were obtained from Asterand (Ann Arbor, MI, USA) and grown according to the supplier's recommendations. HCC1937 cells were obtained from Dr WD Foulkes (McGill University, Montreal, QC, Canada) and were cultured in RPMI-1640 (Invitrogen, Burlington, ON, Canada) supplemented with 10 mM HEPES pH 7.6, 4.5 g/l glucose (Sigma, Oakville, ON, Canada), 1 mM sodium pyruvate (Sigma) and 10% fetal bovine serum. BT474-M1 cells were obtained from Dr Mien-Chie Hung (University of Texas, MD Anderson Cancer Center, Houston, TX, USA). All other breast cancer cell lines were purchased from the American Tissue culture collection (Rockwood MD, ATCC, Manassas, VA, USA) and cultured as recommended. 
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MR Finkbeiner et al COC SUM149 cells were grown to 80% confluency on 15-cm diameter plates (8 Â 10 6 cells). ChIP was performed on the pooled lysates from 12 plates of cells. YB-1:DNA complexes were isolated as described earlier (Wu et al., 2006) using an anti-chicken antibody (Dr Isabella Berquin, Wake Forest University, North Carolina). Following elution of the DNA from the beads, the DNA was amplified using the protocol provided by NimbleGen (additional details can be found in the Supplementary Materials and methods). From the COC hybridization, a list of accession numbers of genes with promoters to which YB-1 potentially binds was generated. Using the National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov/), the accession numbers were decoded and all genes with a greater than log twofold change were identified. Data were analysed using Ingenuity Pathway Analysis software (Redwood City, CA, USA).
Immunoblotting
Breast cancer cell lines were harvested and immunoblotting was performed as described earlier (Wu et al., 2006) by probing the blots with anti-MET (Santa Cruz Biotechnology clone C-12, Santa Cruz, CA, USA), P-YB-1 S102 (Cell Signaling Technologies (CST), Danvers, MA, USA) and total YB-1 (Abcam, Cambridge, MA, USA). Transient transfections were performed with 2 mg of empty vector, Flag:YB-1(WT), Flag:YB-1(D102) or Flag:YB-1(A102) into SUM149 or HCC1937 cells as described earlier (Sutherland et al., 2005) and 72 h later MET receptor levels were evaluated by immunoblotting. Flag YB-1 was detected with an anti-Flag antibody (Sigma) and total YB-1 levels were determined. Actin (CST) was used as a loading control. YB-1 knockdowns were performed as described below, proteins were harvested after 96 h, immunoblotted, and MET and YB-1 levels were determined using Vinculin (Sigma clone Vin 11-5, V4505 antibody) or actin as loading controls. Intensity of the signals was quantified using ImageJ 1.38X image analyzing software.
Immunocytochemistry for P-YB-1 (S102) SUM149 and MDA-MB-231 cells (1.0 Â 10 5 ) were seeded on glass coverslips, washed with phosphate-buffered saline (PBS), fixed with 2% formaldehyde for 20 min, rinsed twice with PBS and then incubated with PBS containing 0.1% Triton X-100 (Sigma) for 30 min. Next, the coverslips were washed with PBS, incubated with rabbit anti-Met (Santa Cruz Biotechnology clone C-12) P-YB-1 (S102) (CST) antibodies dissolved in buffer containing 10% bovine serum albumin and 2% goat serum for 1 h at room temperature in a humidified container. After washing three times with PBS, glass slides were incubated with Alexa 488 anti-rabbit antibody for 1 h, washed three times and then mounted using Vectashield mounting medium (Vector Laboratories, CA, USA). 4,6-diamidino-2-phenylindole was used for nuclear staining.
Isolation of primary progenitor cells
Bipotent progenitor-enriched fractions were isolated from freshly thawed vials of three reduction mammoplasty samples, as described earlier (Eirew et al., 2008 ) (see Supplementary Materials and methods for more detail). We also isolated bipotent progenitor-enriched fractions from three different reduction mammoplasty samples, as described earlier . To assess the transcript levels of YB-1 and MET, 40-60 ng of RNA from each sample were reverse transcribed into cDNA as described . For comparison, RNA was isolated from MDA-MB-231, MDA-MB-468, HCC1937 and SUM149 cells grown in log phase using the Qiagen RNeasy Mini Kit (Qiagen, Mississauga, ON, Canada) and its prescribed protocol. One microgram of extracted RNA was reverse transcribed using Superscript III Reverse Transcriptase and its prescribed protocol (Invitrogen). Quantitative reverse transcriptase-PCR (7000 Sequence Detection System, Applied Biosystems, Streetsvile, ON, Canada) was performed using TaqMan Gene Expression Assays designed against human YB-1 (Custom TAMRA probe, sequence: 6FAM-AAGCCCGGCACTACGGGCAGC-TAMRA, Applied Biosystems), human MET (Assay ID: Hs00179845_m1, Applied Biosystems) and human TATA-box binding protein as an endogenous control (Part No. 4326322E, Applied Biosystems). Relative expression of YB-1 and MET transcript levels was determined by normalizing to TATA-box binding protein.
Traditional ChIP SUM149 and HCC1937 cells were grown until 90% confluent in a 15-cm dish (1 Â 10 7 cells) and ChIP was performed as described earlier (Wu et al., 2006) to isolate the YB-1-promoter complexes. Fifteen potential YB-1 binding sites were identified on the first 2 kb of the MET promoter. Therefore, we designed three sets of primers to narrow down where YB-1 binds to the MET promoter using ChIP. PCR was carried out using 6 ml of purified DNA. Primer sequences were as follows. MET 1: TTGACCTTCACACACCCAGAT (forward), TTCTGAGTTTGAGTGCCATGA (reverse); MET 2: TCATGGCACTCAAACTCAGAA (forward), CCAGTCAG GTGTCCTTCACA (reverse); MET 3: GCAAAATGGTT CAATGCAAG (forward), GGGCCTCGGTGAACTCTATT (reverse). PCR conditions were optimized for the primer sets as follows: 94 1C for 3 min, 40 cycles of 94 1C for 30 s, 58 1C for 30 s and 70 1C for 30 s, followed by 70 1C for 10 min. PCR products were visualized by agarose gel electrophoresis (2% gel) and DNA stained with ethidium bromide (Invitrogen). The YB-1:MET promoter complex was also chromatin immunoprecipitated from a SUM149 xenograft. Briefly, NOD/SCID mice were injected with 5 Â 10 5 cells into the mammary fat pad and the tumors were allowed to develop over a 14-week period. Endogenous YB-1 was subjected to ChIP from the SUM149 xenografts as we described earlier and the DNA was amplified for MET promoter binding using the primers indicated above.
EMSA
Nuclear proteins were isolated from SUM149 and MDA-MB-231 cells using NE-PER extraction kit (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's protocol. The Lightshift Chemiluminescent EMSA kit (Pierce Biotechnology) was used to perform EMSAs using oligonucleotides corresponding to potential YB-1 binding sites according to our earlier published methods (Stratford et al., 2007) . Briefly, binding reactions contained 1 Â binding buffer, 50 ng/ml poly dIdC, 20 fmol biotin-labeled double stranded DNA and 6 mg nuclear extract. unlabeled oligonucleotide (16 pmol) was used as competition. Chicken anti-YB-1 antibody (1 mg) was used to determine YB-1 involvement and cyclic AMP responseelement binding-protein antibody (1 mg) acted as a negative control. Oligo 1: TAACCCATGACTTTCAATAACGAAG ATATC, Oligo 1 mutant: TAACCCATGACTTTCCCCAAC GAAGATATC, Oligo 4: ACTCTTGTAGGTGCCAATTTT TATAGCGAA, Oligo 4 mutant: ACTCTTGTAGGTGC CCCCTTTTATAGCGAA.
Inhibition of YB-1 and MET using siRNA or OSU-03012 The siRNAs targeting YB-1 or MET were diluted in 500 ml serum-free OPTI-MEM (Invitrogen) to achieve a final concentration of 20 nM and 6 ml Lipofectamine RNAiMAX (Invitrogen) was then added. The mixtures were incubated at room temperature for 20 min in the wells of a 6-well plate to each of which 4 Â 10 5 cells were added in 2 ml of media. After 96 h cells were harvested. Small inhibitory RNAs targeting YB-1, referred to as siYB-1 #2 and siYB-1 #3, were obtained from Dharmacon (Lafayette, CO, USA) as described earlier (Stratford et al., 2007) and Qiagen (Catalog number SI03019191), respectively. The siMET oligonucleotide was obtained from Qiagen (Catalog number SI00604821). Stable knockdowns were performed using shYB-1 as described earlier (van Roeyen et al., 2005) in the SUM149 cells.
SUM149 cells were seeded at 85% confluence into 6-well plates 24 h before OSU-03012 treatment. OSU-03012 was added into the media to achieve final concentrations of 10 mM. Equal volumes of dimethylsulfoxide were added as vehicle control treatments. SUM149 cells were harvested at 6 h of OSU-03012 treatment. Western blotting and RT-PCR analyses were performed as described earlier . At later time points, OSU-03012 killed the cells; therefore, we were not able to collect the cells after longer exposure times.
Luciferase assays
To determine the effect of YB-1 expression on MET promoter activity À3.1-kB portion of the receptor was cloned into a pGL2 reporter (Gambarotta et al., 1996) . After 48 (MDA-MB-231 cells) or 72 h (SUM149 cells) of siRNA treatment, cells were transfected with this MET promoter construct, a renilla expression vector, pRL-TK (Promega, Madison, WI, USA) or an empty vector. After an additional 48 (MDA-MB-231 cells) or 24 h (SUM149 cells), cells were harvested in 1 Â Passive Lysis buffer (Promega) and luciferase activity was measured using the Dual Luciferase kit (Promega). Additional cells were lysed in ELB buffer with protease inhibitor cocktail to check for evidence of YB-1 knockdown. Experiments were performed in triplicate on two separate occasions and the results were averaged.
YB-1 overexpression and site-directed mutagenesis
Overexpression of WT and mutated YB-1 A102 was performed as described earlier (Sutherland et al., 2005) . The YB-1 S102D was generated by site-directed mutagenesis (Stratagene, La Jolla, CA, USA) of the WT-YB-1 construct using the following primer: 5 0 -CCAGGAAGTACCTTCGCGATGTA GGAGATGGAGAGACTGTGG-3 0 . These three constructs have the 3x FLAG tag. The plasmid transfections were performed with 2 mg of DNA and Lipofectamine 2000 (Invitrogen), and maintained for 72-96 h.
Effect of siYB-1 on MET receptor signaling and tumor cell growth in soft agar To understand the impact of silencing YB-1 expression on HGF-dependent stimulation of MET receptor signaling, MDA-MB-231 cells were exposed to siYB-1 #2 or siYB-1 #3 for 96 h. Cells were then serum starved over night and then stimulated for 15 min with HGF (20 ng/ml). Proteins were isolated and evaluated for changes in the MET receptor adaptor protein P-Gab-1 (Y307) (Sachs et al., 2000) (CST, cat number 3234). Total Gab-1 was used as a loading control (CST, Cat 3232). To study anchorage independent growth, cells were plated at a density of 1 Â 10 4 cells per well (SUM149 cells) and 2.5 Â 10 3 cells per well (MDA-MB-231 cells) in a 24-well plate in 0.6% agar plus 40 ng/ml HGF (R&D Systems, Minneapolis, MN, USA) on top of a 1.2% cell-free agar. After 28 days, colonies were counted. Experiments were performed in replicates of four on two separate occasions and results averaged.
Abbreviations BLBC, basal-like breast cancer; ChIP, chromatin immunoprecipitation; COC, ChIP-on-chip; CST, Cell Signaling Technologies; EMSA, electrophoretic mobility shift assay; HGF, hepatocyte growth factor; siRNA, small interfering RNA; PBS, phosphate-buffered saline; YB-1, Y-box binding protein-1.
